Headline findings of the BEST3 Trial

This post is from the BEST3 event website, available here. Stay tuned over the coming weeks for more posts about the results from the BEST3 trial!

Join Professors Rebecca Fitzgerald and Peter Sasieni as they discuss the headline findings of the practice-changing BEST3 trial. BEST3 tested a novel device, the Cytosponge, against usual care for detecting the pre-cancerous condition Barrett’s Oesophagus. They are joined by Dr Nick Swart for the health economics analysis. You can find more information about these speakers, and the speakers for upcoming events here.

The views expressed are those of the author. Posting of the blog does not signify that the Cancer Prevention Group endorse those views or opinions.

Share this Page

Subscribe to our mailing list

About Jane Rigney 69 Articles
This post is written by Jane Rigney. Jane is a Clinical Project Manager in the Cancer Prevention Group. She oversees numerous projects, including cancer screening projects, our Patient and Public Involvement (PPI) and general communications.

Be the first to comment

Leave a Reply

Your email address will not be published.


*